Andrea Roberts

Principal Research Scientist

Harvard T.H. Chan School of Public Health
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (12)

Year:

2026

Year:

2026

Year:

2026

Background Several studies have suggested that depression may be associated with increased risk of ovarian cancer. Less is known about whether timing matters regarding when depression occurs. To provide evidence for an etiologically relevant exposure period, we examined depression occurring during the time in which precursor lesions develop and progress to invasive carcinoma with the risk of developing ovarian cancer. Methods Using data from 2 prospective cohorts (1992-2015), we divided follow-up into consecutive 2-year periods for analytic purposes, referred to as “cancer ascertainment periods.” We estimated associations of depression in the 10 years before each cancer ascertainment period with incident cancer, using Cox proportional hazards models. Next, we estimated associations of depression occurring up to 18 years before each ascertainment period, in 2-year increments, with incident cancer. We adjusted for demographic, health, and behavioral factors. All tests of statistical significance were two-sided, with a P-value threshold of less than .05. Results Depression occurring in the 10 prior years was associated with 30% greater risk of cancer (hazard ratio [HR] = 1.30, 95% confidence interval = 1.15 to 1.46). Associations were similar in fully adjusted models (HR = 1.27). Depression occurring in the 14 years before ascertainment was associated with elevated risk, although only estimates for depression 0-2, 6-8, and 8-10 years before ascertainment reached statistical significance (HR range = 1.20-1.36). Conclusion Depression occurring up to 14 years before cancer ascertainment was associated with greater cancer risk. This is the time of precursor progression to invasive ovarian carcinoma, suggesting depression may be an ovarian cancer-promoting agent.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Importance Biomarkers can potentially improve the diagnosis, monitoring, and treatment of posttraumatic stress disorder (PTSD). However, PTSD biomarkers that are scalable and easily integrated into real-world clinical settings have not been identified. Objective To triangulate phenotypic and genomic evidence from a health system biobank with a goal of identifying scalable and clinically relevant biomarkers for PTSD. Design, setting, and participants The analysis was conducted between June to November 2024 using genomic samples and laboratory test results recorded in the Mass General Brigham (MGB) Health System. The analysis included 23,743 European ancestry participants from the nested MGB Biobank study. Exposures The first exposure was polygenic risk score (PRS) for PTSD, calculated using the largest available European ancestry genome-wide association study (GWAS), employing a Bayesian polygenic scoring method. The second exposure was a clinical diagnosis of PTSD, determined by the presence of two or more qualifying PTSD phecodes in the longitudinal electronic health records (EHR). Main outcomes and measures The primary outcomes were the inverse normal quantile transformed, median lab values of 241 laboratory traits with non-zero h 2 SNP estimates. Results Sixteen unique laboratory traits across the cardiometabolic, hematologic, hepatic, and immune systems were implicated in both genomic and phenotypic lab-wide association scans (LabWAS). Two-sample Mendelian randomization analyses provided evidence of potential unidirectional causal effects of PTSD liability on five laboratory traits. Conclusion and relevance These findings demonstrate the potential of a triangulation approach to uncover scalable and clinically relevant biomarkers for PTSD. Key points Question Is genetic liability or diagnosis of PTSD associated with clinical laboratory measures? Findings Among European ancestry participants in the MGB Biobank, we identified 16 unique laboratory traits in cardiometabolic, hematologic, hepatic, and immune systems that were both genetically and phenotypically associated with PTSD, with five markers demonstrating potential unidirectional causal effects of PTSD liability. Meaning Our findings reveal associations between PTSD and laboratory markers across multiple physiological systems, with evidence suggesting possible unidirectional causal effects of PTSD liability on cardiometabolic, hematologic, and hepatic markers.

Year:

2025

Research has suggested that mental illness may be a risk factor for, as well as a sequela of, experiencing intimate partner violence (IPV). The association between IPV and mental illness may also be due in part to gene-environment correlations. Using polygenic risk scores for six psychiatric disorders - attention-deficit hyperactivity disorder (ADHD), autism spectrum disorder (ASD), bipolar disorder (BPD), major depressive disorder (MDD), neuroticism, and schizophrenia—and a combined measure of overall genetic risk for mental illness, we tested whether women’s genetic risk for mental illness was associated with the experience of three types of intimate partner violence. In this cohort of women of European ancestry ( N = 11,095), participants in the highest quintile of genetic risk for ADHD (OR range: 1.38–1.49), MDD (OR range: 1.28–1.43), neuroticism (OR range: (1.18–1.25), schizophrenia (OR range: 1.30–1.34), and overall genetic risk (OR range: 1.30–1.41) were at higher risk for experiencing more severe emotional and physical abuse, and, except schizophrenia, more severe sexual abuse, as well as more types of abuse and chronic abuse. In addition, participants in the highest quintile of genetic risk for neuroticism (OR = 1.43 95% CI: 1.18, 1.72), schizophrenia (OR = 1.33 95% CI: 1.10, 1.62), and the overall genetic risk (OR = 1.40 95% CI: 1.15, 1.71) were at higher risk for experiencing intimate partner intimidation and control. Participants in the highest quintile of genetic risk for ADHD, ASD, MDD, schizophrenia, and overall genetic risk, compared to the lowest quintile, were at increased risk for experiencing harassment from a partner (OR range: 1.22–1.92). No associations were found between genetic risk for BPD with IPV. A better understanding of the salience of the multiple possible pathways linking genetic risk for mental illness with risk for IPV may aid in preventing IPV victimization or re-victimization.

Year:

2024

Animal studies have shown that exposure to cigarette smoke during pregnancy can induce neurobehavioral anomalies in multiple subsequent generations. However, little work has examined such effects in humans. We examined the risk of grandchild autism spectrum disorder (ASD) in association with grandmother’s smoking during pregnancy, using data from 53 562 mothers and grandmothers and 120 267 grandchildren in Nurses’ Health Study II. In 1999, Nurses’ Health Study II participants with children reported on their mothers’ smoking. Grandchildren’s ASD diagnoses were reported by the mothers in 2005 and 2009. Among grandmothers, 13 383 (25.0%) smoked during pregnancy, and 509 (0.4%) grandchildren were diagnosed with ASD. The adjusted odds ratio for ASD for grandmother smoking during pregnancy was 1.52 (95% CI, 1.06-2.20). Results were similar with direct grandmother reporting in 2001 of her smoking during pregnancy from the Nurses’ Mothers Cohort Study subgroup (n = 22 167 grandmothers, n = 49 917 grandchildren) and were stronger among grandmothers who smoked ≥15 cigarettes per day during pregnancy (adjusted odds ratio = 1.93 [95% CI, 1.10-3.40]; n = 1895 grandmothers, n = 4212 grandchildren). Results were similar when we adjusted for mother’s smoking during pregnancy. There was no association with grandfather’s smoking as reported by the grandmother. Our results suggest a potential persistent impact of gestational exposure to environmental insults across 3 generations.

Year:

2024

Year:

2023

Year:

2023

Collaborators (10)

Jordan Smoller

Professor

Massachusetts General Hospital

UNITED STATES
View details

Jennifer A. Sumner

Assistant Professor

University of California, Los Angeles

UNITED STATES
View details

Shanlin Ke

Assistant Professor

Ohio State University

UNITED STATES
View details

Tian Ge

Broad Institute

UNITED STATES
View details

Caroline Nievergelt

Professor

University of California, San Diego

UNITED STATES
View details

Lori Chibnik

Massachusetts General Hospital

UNITED STATES
View details

Mingyang Song

Associate Professor

Harvard University

UNITED STATES
View details

Jakob Hartmann

Harvard University

UNITED STATES
View details

Justin D Tubbs

Assistant Professor

Massachusetts General Hospital

UNITED STATES
View details

Mary Townsend

Senior Staff Scientist

Knight Cancer Institute, Oregon Health and Science University

UNITED STATES
View details